MarketCapExport financials
Rigel Pharmaceuticals (RIGL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Rigel Pharmaceuticals Balance Sheet 2025-2008 | RIGL
Brief overview of Rigel Pharmaceuticals's balance sheet strength
The comparison uses five available annual reports from the 2021–2025 interval.
Assets reached $513.6 million, compared with $167.3 million at the beginning. Growth of +206.9% and CAGR near 32.4% show active expansion.
Liabilities grew more slowly than assets: -10.8% versus +206.9%. Expansion relied more on equity, improving funding quality.
Internal capital represents 76.2% of the balance sheet, previously 18.2%. This is a strong capital position.
Each unit of equity supports about 0.03x of net debt. Dependence on debt remains comfortable.
The cash share moved from 11.3% to 7.9%. A higher figure generally provides more room in an adverse scenario.
Retained earnings remain negative at -$1 billion. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
The indicators point to a strong balance sheet position for Rigel Pharmaceuticals: funding is balanced and liability risks appear controlled.
Annual Balance Sheet Rigel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
12.5 M | 3.54 M | 27.9 M | 16.7 M | -8.24 M | -1.94 M | 62.8 M | -76.3 M | -38.3 M | -17.6 M | -43.5 M | -15.2 M | -20.9 M | -33.5 M | -18.6 M | - | - | - |
Long Term Debt |
52.5 M | 60 M | 60 M | 40 M | 759 K | 19.8 M | 9.81 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
614 K | 285 K | 692 K | 1.13 M | 9.89 M | 8.62 M | 7.27 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 35.5 M | 1.5 M | 128 K | 519 K | 6.57 M | 11.9 M | 7.51 M | 8.74 M | 9.43 M | - | - | - |
Total Current Liabilities |
99.2 M | 63.3 M | 53.3 M | 65.2 M | 63.6 M | 40.8 M | 58.2 M | 27.7 M | 18.3 M | 22.6 M | 33.8 M | 14 M | 10.3 M | 12.2 M | 11.5 M | 11.3 M | - | - |
Total Liabilities |
122 M | 161 M | 146 M | 148 M | 137 M | 76.4 M | 93.8 M | 29.2 M | 18.5 M | 23.1 M | 40.4 M | 25.9 M | 17.8 M | 20.9 M | 21 M | - | - | - |
Deferred Revenue |
1.36 M | 1.36 M | 1.36 M | 1.37 M | 2.6 M | 3.02 M | 25.3 M | 1.03 M | - | - | 13.4 M | - | - | 666 K | 129 K | - | - | - |
Retained Earnings |
-1.02 B | -1.39 B | -1.41 B | -1.38 B | -1.32 B | -1.31 B | -1.28 B | -1.21 B | -1.14 B | -1.06 B | -992 M | -940 M | -849 M | -760 M | -661 M | -575 M | - | - |
Total Assets |
514 M | 164 M | 117 M | 134 M | 167 M | 110 M | 148 M | 139 M | 119 M | 78.1 M | 132 M | 154 M | 226 M | 310 M | 257 M | 187 M | - | - |
Cash and Cash Equivalents |
40.6 M | 56.7 M | 32.8 M | 24.5 M | 18.9 M | 30.4 M | 22.5 M | 76.3 M | 38.3 M | 17.6 M | 43.5 M | 15.2 M | 20.9 M | 33.5 M | 18.6 M | 8.88 M | 14.7 M | 46 M |
Book Value |
391 M | 3.29 M | -28.6 M | -13.6 M | 30.4 M | 34 M | 53.8 M | 110 M | 101 M | 55 M | 91.4 M | 128 M | 208 M | 289 M | 236 M | 187 M | - | - |
Total Shareholders Equity |
391 M | 3.29 M | -28.6 M | -13.6 M | 30.4 M | 34 M | 53.8 M | 110 M | 101 M | 55 M | 91.4 M | 128 M | 208 M | 289 M | 236 M | 166 M | 110 M | 104 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Rigel Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
58 K | 45 M | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M | 972 K | 40 M | - | 30 M | 759 K | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 10 M | 10 M | 10 M | 19.2 M | 19.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
95.6 M | 105 M | 125 M | 125 M | 157 M | 154 M | 158 M | 158 M | 147 M | 145 M | 148 M | 148 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 1.36 M | 1.36 M | 1.36 M | 1.36 M | 1.36 M | 1.36 M | 1.36 M | 1.36 M | 1.37 M | 1.37 M | 1.37 M | - | 2.1 M | 2.6 M | 3.16 M | 5.81 M | 9.5 M | 3.02 M | 3.02 M | 3.02 M | 3.02 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | - | - | - | - | - | - | 3.76 M | 8.59 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105 K | - |
Retained Earnings |
-997 M | -1.01 B | -1.29 B | -1.32 B | -1.38 B | -1.4 B | -1.42 B | -1.42 B | -1.41 B | -1.4 B | -1.4 B | -1.38 B | -1.38 B | - | -1.35 B | -1.32 B | -1.3 B | -1.28 B | -1.27 B | -1.31 B | -1.31 B | -1.31 B | -1.31 B | -1.28 B | -1.28 B | -1.28 B | -1.28 B | -1.21 B | -1.21 B | -1.21 B | -1.21 B | -1.14 B | -1.14 B | -1.14 B | -1.14 B | -1.06 B | -1.06 B | -1.06 B | -1.06 B | -992 M | -992 M | -992 M | -992 M | -940 M | -940 M | -940 M | -940 M | -849 M | -849 M | -849 M | -849 M | -760 M | -760 M | -760 M | -760 M | -661 M | -661 M | -661 M | -661 M |
Total Assets |
521 M | 505 M | 243 M | 207 M | 176 M | 139 M | 128 M | 127 M | 115 M | 117 M | 124 M | 134 M | 116 M | - | 149 M | 167 M | 187 M | 202 M | 216 M | 110 M | 110 M | 110 M | 110 M | 148 M | 148 M | 148 M | 148 M | 139 M | 139 M | 139 M | 139 M | 119 M | 119 M | 119 M | 119 M | 78.1 M | 78.1 M | 78.1 M | 78.1 M | 132 M | 132 M | 132 M | 132 M | 154 M | 154 M | 154 M | 154 M | 226 M | 226 M | 226 M | 226 M | 310 M | 310 M | 310 M | 310 M | 257 M | 257 M | 257 M | 257 M |
Cash and Cash Equivalents |
60.8 M | 24.4 M | 48.5 M | 53.4 M | 45.8 M | 51.7 M | 36.1 M | 25.6 M | 45.4 M | 48.8 M | 40.3 M | 24.5 M | 29.9 M | 27.2 M | 24.7 M | 18.9 M | 30.4 M | 84.8 M | 20 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 38.3 M | 38.3 M | 38.3 M | 38.3 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M |
Book Value |
425 M | 400 M | 118 M | 81.9 M | 18.6 M | -14.6 M | -29.9 M | -31.7 M | -31.8 M | -28.1 M | -24.3 M | -13.6 M | 116 M | - | 149 M | 167 M | 187 M | 202 M | 216 M | 110 M | 110 M | 110 M | 110 M | 148 M | 148 M | 148 M | 148 M | 139 M | 139 M | 139 M | 139 M | 119 M | 119 M | 119 M | 119 M | 78.1 M | 78.1 M | 78.1 M | 78.1 M | 132 M | 132 M | 132 M | 132 M | 154 M | 154 M | 154 M | 154 M | 226 M | 226 M | 226 M | 226 M | 310 M | 310 M | 310 M | 310 M | 257 M | 257 M | 257 M | 257 M |
Total Shareholders Equity |
425 M | 400 M | 118 M | 81.9 M | 18.6 M | -14.6 M | -29.9 M | -31.7 M | -31.8 M | -28.1 M | -24.3 M | -13.6 M | -19.8 M | -3.68 M | 6.8 M | 30.4 M | 49.7 M | 68.1 M | 78.3 M | 34 M | 34 M | 34 M | 34 M | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 110 M | 110 M | 110 M | 110 M | 101 M | 101 M | 101 M | 101 M | 55 M | 55 M | 55 M | 55 M | 91.4 M | 91.4 M | 91.4 M | 91.4 M | 128 M | 128 M | 128 M | 128 M | 208 M | 208 M | 208 M | 208 M | 289 M | 289 M | 289 M | 289 M | 236 M | 236 M | 236 M | 236 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Rigel Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
